metronidazole has been researched along with Carcinogenesis in 3 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Carcinogenesis: The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metronidazole is an antibiotic widely used in different medical conditions such as trichomoniasis, amoebiasis, and giardiasis among others." | 2.61 | Therapeutic uses of metronidazole and its side effects: an update. ( Hernández Ceruelos, A; López Contreras, L; Romero-Quezada, LC; Ruvalcaba Ledezma, JC, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullman, S | 1 |
| Pedamallu, CS | 1 |
| Sicinska, E | 1 |
| Clancy, TE | 1 |
| Zhang, X | 1 |
| Cai, D | 1 |
| Neuberg, D | 1 |
| Huang, K | 1 |
| Guevara, F | 1 |
| Nelson, T | 1 |
| Chipashvili, O | 1 |
| Hagan, T | 1 |
| Walker, M | 1 |
| Ramachandran, A | 1 |
| Diosdado, B | 1 |
| Serna, G | 1 |
| Mulet, N | 1 |
| Landolfi, S | 1 |
| Ramon Y Cajal, S | 1 |
| Fasani, R | 1 |
| Aguirre, AJ | 1 |
| Ng, K | 1 |
| Élez, E | 1 |
| Ogino, S | 1 |
| Tabernero, J | 1 |
| Fuchs, CS | 1 |
| Hahn, WC | 1 |
| Nuciforo, P | 1 |
| Meyerson, M | 1 |
| Hernández Ceruelos, A | 1 |
| Romero-Quezada, LC | 1 |
| Ruvalcaba Ledezma, JC | 1 |
| López Contreras, L | 1 |
| Dingemanse, C | 1 |
| Belzer, C | 1 |
| van Hijum, SA | 1 |
| Günthel, M | 1 |
| Salvatori, D | 1 |
| den Dunnen, JT | 1 |
| Kuijper, EJ | 1 |
| Devilee, P | 1 |
| de Vos, WM | 1 |
| van Ommen, GB | 1 |
| Robanus-Maandag, EC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rectal Microbiome Variability Among Rectal Cancer Cohorts Including Complete Clinical Responders, Pathologic Responders, and Early Recurrence[NCT04223102] | 40 participants (Anticipated) | Interventional | 2020-02-18 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metronidazole and Carcinogenesis
| Article | Year |
|---|---|
Therapeutic uses of metronidazole and its side effects: an update.
Topics: Animals; Antiprotozoal Agents; Carcinogenesis; Disease Models, Animal; DNA Damage; Drug Utilization; | 2019 |
2 other studies available for metronidazole and Carcinogenesis
| Article | Year |
|---|---|
Analysis of
Topics: Adenocarcinoma; Animals; Anti-Bacterial Agents; Bacteroides; Carcinogenesis; Colorectal Neoplasms; F | 2017 |
Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Carcinogenesis; Clarithromycin; Drug Therapy, Combinati | 2015 |